Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3826876 | 0.81 | KCNN4 (0.33) | KCNN4KCNA3 | |
| SCHEMBL70574 | 0.76 | L3MBTL1 (0.44) | KCNN4KCNA3ALDH1A1HPGDMEN1 | |
| SCHEMBL29771432 | 0.76 | L3MBTL1 (0.41) | KCNN4KCNA3HPGDMEN1KMT2A | |
| SCHEMBL19989137 | 0.73 | KDM4E (0.40) | KCNN4KCNA3ALDH1A1HPGDLMNA | |
| SCHEMBL18229954 | 0.73 | KCNN4 (0.42) | KCNN4KCNA3MEN1HTTKMT2A | |
| SCHEMBL580662 | 0.70 | NPC1 (0.39) | KCNN4KCNA3ALDH1A1GAANPSR1 | |
| SCHEMBL29520095 | 0.70 | FGFR3 (0.47) | SCD | |
| SCHEMBL15594489 | 0.70 | ALDH1A1 (0.35) | ALDH1A1MEN1HTTKMT2ALMNA | |
| SCHEMBL509162 | 0.70 | FGFR3 (0.47) | SCD | |
| SCHEMBL240423 | 0.70 | RAB9A (0.50) | ALDH1A1HPGDMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892904-B1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | CB THERAPEUTICS INC (KY) | 2018-10-17 | — | — | EP | disclosed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | disclosed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | disclosed |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | APOLLOMICS INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | APOLLOMICS INC. | 2015-08-06 | — | — | US | disclosed |
| EP-2892904-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | Crown Bioscience Inc. (Taiwan) (CN) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014032498-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | CROWN BIOSCIENCE INC. (TAICANG) (CN) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032498-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | CROWN BIOSCIENCE INC. (TAICANG) (CN) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | MET, MYC, HGFAC | KCNN4 4403/4885KCNA3 4693/4885ALDH1A1 3438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.